RTTNews | Nov 9, 2020 10:52AM EST

10:51 Monday, November 9, 2020 (RTTNews.com) - Shares of Calliditas Therapeutics AB (CALT) surged over 30% on Monday morning after the company announced positive topline results from a pivotal late-stage study of a chronic kidney disease treatment.

CALT is currently trading at $33.00, up $7.83 or 31.11%, on the Nasdaq.

The Phase 3 trial NefIgArd, which investigated the effect of Nefecon versus placebo in patients with primary IgA nephropathy, met its primary objective of demonstrating a statistically significant reduction in urine protein creatinine ratio after 9 months of treatment.

The trial also met the key secondary endpoint showing a statistically significant difference in estimated glomerular filtration rate after 9 months of treatment.

IgA nephropathy is a chronic kidney disease. It progresses over 10 to 20 years, and it can lead to end-stage renal disease. It is caused by deposits of the protein immunoglobulin A (IgA) inside the filters (glomeruli) in the kidney.

Read the original article on RTTNews ( https://www.rttnews.com/3144433/stock-alert-calliditas-therapeutics-jumps-30-on-positive-results-from-kidney-disease-drug-trial.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2020 RTTNews.com All Rights Reserved